BioNTech on it's way to new highs
Positive Outlook: New ATH
Indicators: Neutral to Bullish
Trend: overall bullish
Stop-Loss: 180 EUR
Target: 220 - 240 EUR
BioNTech got the approval for it's vaccine (for the use for children at 12 or older) from the EMA end ofMay. This boosted the stock above the resistance at 169 EUR which would break the first range it's trading in. The second, much larger range, was beaten a few days after. It's defined by an inside bar on the daily view. Because of this, a fallback into that range could lead to larger consolidation. Therefore, we put our stop loss just below the last ATH. Target remains in the area between the 38,2 and 61,8 Fib (220 - 240 EUR). Next few days (1-2) will be a little bit of Mid-Consolidation before picking up again.
Let's see what happens.
Indicators: Neutral to Bullish
Trend: overall bullish
Stop-Loss: 180 EUR
Target: 220 - 240 EUR
BioNTech got the approval for it's vaccine (for the use for children at 12 or older) from the EMA end ofMay. This boosted the stock above the resistance at 169 EUR which would break the first range it's trading in. The second, much larger range, was beaten a few days after. It's defined by an inside bar on the daily view. Because of this, a fallback into that range could lead to larger consolidation. Therefore, we put our stop loss just below the last ATH. Target remains in the area between the 38,2 and 61,8 Fib (220 - 240 EUR). Next few days (1-2) will be a little bit of Mid-Consolidation before picking up again.
Let's see what happens.
관련 발행물
면책사항
이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.